IPOs: Red-Hot or Destined to Flop?

IPO is a phrase that conjures magical ideas of untold wealth for investors. Are these red-hot opportunities a good strategy, or should investors steer clear?  [Browser View]( [Liberty Through Wealth]( Should You Bet Big on the Latest Red-Hot IPO? Nicholas Vardy, ETF Strategist, The Oxford Club  IPO is a phrase that conjures magical ideas of untold wealth for investors. But are these red-hot opportunities actually a good investment strategy?  Today, Nicholas Vardy explains how investors can safely profit from the latest IPOs.  [Bill O'Reilly's Wild Money Secret](  [Bill O'Reilly Video Thumbnail](  [In a tell-all video, Bill O'Reilly reveals the shocking way YOU can retire with a seven-figure nest egg.](  [Nicholas Vardy]  For many investors, IPO - initial public offering - is a magical phrase. As a reminder, an IPO happens when a company first lists on a stock exchange and investors can buy its stock in their brokerage accounts. I was in New York City when Facebook (Nasdaq: FB) IPO'd on May 18, 2012. The electronic screens in Times Square were awash with Facebook logos. CNBC covered the event with breathless enthusiasm, monitoring every tick of the stock. Had you invested in Facebook that day at $38 a share - and held on even when it dropped to $18 - you'd be a happy camper today. Yesterday, Facebook closed at around $193. That works out to an average annual return of about 26% per year. IPO Market: The Dot-Com Boom vs. Today The heyday of IPOs in the U.S. stock market was, of course, [the dot-com boom of the 1990s](. Silicon Valley IPOs minted millionaires at a furious pace as share prices soared on the first day of trading. In 1998, eBay (Nasdaq: EBAY) listed at $18 a share. By the end of the first day of trading, it had leapt to $53. By 1999, the market was even hotter. Priceline, now Booking Holdings (Nasdaq: BKNG), also listed at $18. By the close of business that day, shares traded hands at $82.50. Alas, today's IPO landscape is very different. That's because most high-profile IPOs have been duds. Whether it's Blue Apron (NYSE: APRN), Uber (NYSE: UBER), Snap (NYSE: SNAP) or Lyft (Nasdaq: LYFT)... Each of these companies' shares are trading below their IPO price. Take the example of [ride-hailing giant Uber](. Its share price recently tumbled to its lowest point yet: $25.58. That's versus its IPO price of $45. (Uber founder Travis Kalanick dumping $540 million worth of Uber shares in the market didn't help.) So the question arises... Should you even bother investing in an IPO? Recently, Verdad - a Seattle-based hedge fund firm - examined just that topic. And its conclusion was clear as day. Despite the success you may have had with Facebook... Steer clear of shiny new IPOs. They could end up costing you a lot of money. Let me explain...  ["It's Impossible... but I've Beaten Science."](  [Happy Woman in Wheelchair]( When doctors discovered her cancer, they gave Sharon J. six weeks to live. Years later, [she's alive and well](. Doctors can't explain it... but Sharon can. She credits her miraculous recovery to what some call the "[divine medicine](." It may be one of the most powerful [natural disease fighters]( in existence. [Go HERE for the full story.]( SPONSORED  The Lure of a Sexy IPO A well-pitched IPO sucks an investor in. You get to invest in a compelling, exciting growth story... and you have the prospect of getting rich in the process. (A friend of mine always joked that every new bouncing baby could grow up to be president. Alas, by the time they hit the age of 14, it is far more likely that they just turned into another pimply, obstreperous teenager.) Verdad ran the numbers for 3,700 IPOs dating back to the late 1980s. The median lost 31% of its value from the date of the IPO to the closing price on the same date three years later. Hold on for five years, and the average loss grows to 41%. The longer-term returns are even worse. Had you bought and held on to each of the IPOs, you'd have lost about half your wealth 50% of the time... and 75% of your wealth a quarter of the time. Ouch. [That's a long way]( from cranking out 26% average returns by investing in Facebook... or quadrupling your money on the first day in Priceline. Put another way, investing in the bouncing baby boys of the investment world may be the easiest way to lose nearly all your money. How to Best Invest in IPOs At first blush, Verdad's conclusions suggest that you should never invest in IPOs. But there is another way... You can apply a disciplined strategy to investing in IPOs through an ETF. The First Trust US Equity Opportunities ETF (NYSE: FPX) tracks a market cap-weighted index of the 100 largest U.S. IPOs over the first 1,000 trading days for each stock. The First Trust Opportunities ETF invests in eligible stocks after the close on the sixth trading day and sells them on the 1,000th day. That makes its average holding period roughly four years. Here's the critical part... The ETF does not invest in all IPO stocks. Instead, it applies quantitative screens to each potential investment. It also imposes minimum size and liquidity requirements. This selection process has ensured that the First Trust Opportunities ETF has minimal, if any, exposure to the recent IPO duds mentioned above. As the chart below confirms, the strategy has substantially outperformed the S&P 500 over its lifetime.  [First Trust US Equity Opportunities ETF vs S&P 500 Lifetime Performance]  So should you invest in individual IPOs? Well, the odds are against you. But invest in a disciplined strategy that identifies the right IPOs... And consistent, market-beating returns could be yours. Good investing, Nicholas P.S. I'm watching Ken Burns' classic documentary [The Civil War]( (available on Netflix). It explores the gut-wrenching battles between North and South with compelling personal stories. --------------------------------------------------------------- Interested in hearing more from Nicholas? Follow [@NickVardy]( on Twitter. [Leave a Comment](  [Facebook]( [Twitter]( [share](mailto:?subject=A%20great%20piece%20from%20Liberty%20Through%20Wealth...&body=From%20Liberty%20Through%20Wealth:%0D%0A%0D%0A IPO%20is%20a%20phrase%20that%20conjures%20magical%20ideas%20of%20untold%20wealth%20for%20investors.%20Are%20these%20red-hot%20opportunities%20a%20good%20strategy,%20or%20should%20investors%20steer%20clear?%20%0A%0D ?src=shared)  About Nicholas  Nicholas Vardy is the ETF Strategist of The Oxford Club, head of Oxford Wealth Accelerator, and contributor to Liberty Through Wealth and [The Oxford Communiqué](. He is a widely recognized expert on exchange-traded funds whose work has been cited in a variety of publications, including The Wall Street Journal and Financial Times. He holds a B.A. and M.A. from Stanford University and a J.D. from Harvard Law School. He is also an associate of the Adam Smith Institute and the Chatham House think tank in London.  [THIS Is What Some Doctors Do When They Want Pain Relief (Hint: It's NOT Pills)]( [Back Pain]( Today we're blowing the lid off the best-kept pain secret in the medical community. This [ONE controversial compound]( could eliminate your pain, starting in seven seconds or less. Washington, D.C., physician Dr. Will Cole says, "It's one of the things that I use every day." [Click here to END your chronic pain for good.]( SPONSORED  More From Liberty Through Wealth  [Scientist]( [Why First Impressions Matter]( By Alexander Green When Alex met The Oxford Club's newest strategist in 2007, he was skeptical. But it turns out they share a common strategy and interest: biotech stocks. [Brandenburg Gate]( [Remembering the Fall of the Berlin Wall]( By Nicholas Vardy The Berlin Wall came down 30 years ago, signifying the end of the Soviet Union. Today, we reflect on its significance and lasting impact on global wealth. [Rose Colored Glasses]( [The World Really Isn't Going to Hell... Here's Why]( By Alexander Green A clear-eyed view of our nation and the world is essential for building wealth and a rich life, but that can seem impossible with constant media negativity. You are receiving this email because you subscribed to Liberty Through Wealth. To unsubscribe from Liberty Through Wealth, [click here](. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Liberty Through Wealth | Attn: Member Services | P.O. Box 932, Baltimore, MD 21203 North America: [1.877.806.4508]( | International: [+1.443.353.4610]( | Fax: [1.410.329.1923]( Website: [www.libertythroughwealth.com]( Keep the emails you value from falling into your spam folder. [Whitelist Liberty Through Wealth](. © 2019 The Oxford Club LLC All Rights Reserved [Oxford Club] The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.